APPILI THERAPEUTICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.04 CAD | +14.29% |
|
-11.11% | +14.29% |
| Apr. 02 | Appili Therapeutics To be Acquired by Aditxt, Inc. | MT |
| Apr. 02 | Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. for $6.7 million. | CI |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 4.85M 3.53M |
|---|---|---|---|---|---|
| Net income 2024 * | -6M -4.36M | Net income 2025 * | -10M -7.27M | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-0.74
x | P/E ratio 2025 * |
-0.74
x | Employees | 9 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.94% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +14.29% | ||
| 1 week | -11.11% | ||
| Current month | +14.29% | ||
| 1 month | +14.29% | ||
| 3 months | +33.33% | ||
| 6 months | +14.29% | ||
| Current year | +14.29% |
1 week
0.04
0.04
1 month
0.030.06
Current year
0.030.06
1 year
0.030.08
3 years
0.031.31
5 years
0.031.89
10 years
0.031.89
| Managers | Title | Age | Since |
|---|---|---|---|
Don Cilla
CEO | Chief Executive Officer | 63 | 20-10-31 |
Armand Balboni
CHM | Chairman | 57 | 18-09-30 |
Kenneth Howling
DFI | Director of Finance/CFO | 66 | 21-11-15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 20-01-26 | |
Prakash Gowd
BRD | Director/Board Member | 60 | Nov. 12 |
| Director/Board Member | 70 | 21-02-01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-19 | 0.04 | +14.29% | 99,000 |
| 24-04-18 | 0.035 | 0.00% | 5,000 |
| 24-04-17 | 0.035 | -12.50% | 331,000 |
| 24-04-16 | 0.04 | +14.29% | 228,500 |
| 24-04-15 | 0.035 | -22.22% | 2,194,795 |
Delayed Quote Toronto S.E., April 19, 2024 at 01:06 pm EDT
More quotes
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Companyâs anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.
Calendar
2024-06-25
- Q4 2024 Earnings Release (Projected)
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.29% | 3.53M | |
| -3.10% | 102B | |
| +2.11% | 96.37B | |
| -1.80% | 21.37B | |
| -17.75% | 20.92B | |
| -6.91% | 18.64B | |
| -42.00% | 16.4B | |
| -28.19% | 13.53B | |
| +19.90% | 10.85B | |
| -23.23% | 8.4B |
- Stock Market
- Equities
- APLI Stock
